News for AC Immune SA (ACIU)

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ACI-7104.056 in the treatment of early Parkinson’s disease.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling by more than 150 points on Thursday. The Dow traded down 0.38% to 43,790.8...

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Thursday. Shares of Hillenbrand, Inc. HI rose sharply in today's session follo...

**media[464664]**

**media[456652]**

AC Immune SA (ACIU) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue is $1.71 million, and the earnings are ex

Shares of Granite Point Mortgage Trust Inc. GPMT rose sharply in today's pre-market trading after the company announced a third-quarter common and preferred sto...

AC Immune receives a milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for progress in phase 2b ReTain trial.

AC Immune SA (ACIU), a clinical-stage biopharmaceutical company, Tuesday said it will receive the second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, Inc.

Maryland-based biotechnology company Gain Therapeutics, Inc. (GANX) is down over 27 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Loading... Loading... Shares of SentinelOne, Inc. S shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentinel...

Morning Reads

Pune, India, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer's drugs which in turn is ...

February 12, 2021 (Investorideas.com Newswire) Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzhei...

Shares of AC Immune SA (ACIU) are currently gaining 35% on Thursday morning after the Switzerland-based clinical-stage biopharmaceutical company announced positive interim results from ongoing mid-stage trial in older patients with early Alzheimer's disease.